Quest Diagnostics upgraded by Robert W. Baird with a new price target
$DGX
Medical Specialities
Health Care
Robert W. Baird upgraded Quest Diagnostics from Neutral to Outperform and set a new price target of $182.00 from $157.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/23/2024 | $157.00 → $182.00 | Neutral → Outperform | Robert W. Baird |
| 8/28/2024 | $165.00 | In-line | Evercore ISI |
| 7/10/2024 | $145.00 → $165.00 | Neutral → Buy | Citigroup |
| 2/26/2024 | $135.00 | Market Perform | Leerink Partners |
| 2/7/2024 | $140.00 → $155.00 | Hold → Buy | Jefferies |
| 1/3/2024 | $145.00 | Equal Weight | Barclays |
| 12/12/2023 | $140.00 → $160.00 | Neutral → Buy | BofA Securities |
| 6/29/2023 | Neutral | Piper Sandler |
The joint offerings will range from exploratory panel development to the manufacturing and distribution of FDA-approved diagnostic kits.
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Quest Diagnostics (NYSE:DGX) in the last three months. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 4 0 0 Last 30D 0 0 1 0 0 1M Ago 1 0 2 0 0 2M Ago 0 0 1 0 0 3M Ago 0 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $157.0, a high estimate of $165.00, and a low estimate of $153.00. Marking an increase of 5.37%, the
Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $153 to $154.
Third quarter revenues of $2.49 billion, up 8.5% from 2023Third quarter reported diluted earnings per share ("EPS") of $1.99, up 1.5% from 2023; and adjusted diluted EPS of $2.30, up 3.6% from 2023Full year 2024 revenues now expected to be between $9.80 billion and $9.85 billion; reported diluted EPS now expected to be between $7.60 and $7.70; and adjusted diluted EPS expected to be between $8.85 and $8.95SECAUCUS, N.J., Oct. 22, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2024.
SECAUCUS, N.J., Sept. 25, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leader in diagnostic information services, announced that it will report third quarter 2024 financial results on Tuesday, October 22, 2024, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www
SECAUCUS, N.J., Aug. 14, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on October 21, 2024 to shareholders of record of Quest Diagnostics common stock on October 4, 2024. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to ta
10-Q - QUEST DIAGNOSTICS INC (0001022079) (Filer)
8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)
8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
Robert W. Baird upgraded Quest Diagnostics from Neutral to Outperform and set a new price target of $182.00 from $157.00 previously
Evercore ISI resumed coverage of Quest Diagnostics with a rating of In-line and set a new price target of $165.00
Citigroup upgraded Quest Diagnostics from Neutral to Buy and set a new price target of $165.00 from $145.00 previously
Quest to develop laboratory tests and support public health reporting and laboratory readiness for CDC's preparedness strategy; Company to introduce clinical testing for avian flu later this month based on one of the awards SECAUCUS, N.J., Oct. 23, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, today announced that it has been awarded several contracts by the U.S. Centers for Disease Control and Prevention (CDC) to support testing and sustained laboratory readiness for two emerging infectious diseases recently identified in people in the Americas.
Third quarter revenues of $2.49 billion, up 8.5% from 2023Third quarter reported diluted earnings per share ("EPS") of $1.99, up 1.5% from 2023; and adjusted diluted EPS of $2.30, up 3.6% from 2023Full year 2024 revenues now expected to be between $9.80 billion and $9.85 billion; reported diluted EPS now expected to be between $7.60 and $7.70; and adjusted diluted EPS expected to be between $8.85 and $8.95SECAUCUS, N.J., Oct. 22, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2024.
First-of-its-kind service empowers discreet and more convenient access to testing and treatment for vaginitis and similar genital tract infections such as chlamydia, gonorrhea, trichomoniasis and Mycoplasma genitalium Self-collection option available at no extra charge at any of Quest's 2,000 patient service centers with a physician's order or through Quest's consumer-initiated test platform at questhealth.com SECAUCUS, N.J., Oct. 15, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced the availability of a new service aimed at increasing convenience and speed of testing and treatment of several common genital tract infections (GTI
SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)
SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)
SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)
Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh
SECAUCUS, N.J., March 3, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors elected James E. Davis, the company's Chief Executive Officer and President, to serve in the additional position of Chairman of the Board of Directors, effective April 1, 2023. "The Board carefully considered our governance structure and determined that combining the roles of Chairman and CEO under Jim Davis's leadership is in the best interest of shareholders to successfully continue to execute
JERSEY, Channel Islands, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Ali Kiboro as the Company's Chief Financial Officer (CFO). Mr. Kiboro will assume the responsibilities of CFO on November 1st, 2021, replacing Mr. Peter Buhler who will support the Company during the transitional phase, as needed, before leaving Quotient Limited at year-end. "I am delighted to welcome Ali to the Executive team at this exciting time in our Company's evolution. He brings over 20 years of experience in global finance and has been a key driver of operational excellence in a career spanning healthcare services and manufacturing. I w